1. Corporate Strategy

Compliance is Futile Without Transparency: 340B, MDRP, MFP Overlap Lead to Iceberg Ahead

Today’s guest post comes from Angie Franks, CEO at Kalderos

Angie describes the compliance challenges that stakeholders face in managing the complex interactions of the 340B Drug Pricing Program, the Medicaid Drug Rebate Program, and IRA’s Maximum Fair Price and inflation rebate provisions. She explains how clean, comprehensive claims data can resolve these issues.

To learn more, register for Kaldreros’ March 4 free webinar: Taking Action Amidst 340B Uncertainty With Truzo.

Read on for Angie’s insights.


Read more »

       
View Original Article
https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!